June 22, 2022
Robbins Geller Rudman & Dowd LLP asked Tuesday for a one-third cut of a $15 million settlement that investors won from OvaScience and its venture capital backer Longwood Fund over shareholder losses allegedly caused by misrepresentations about the success of a new fertility treatment.
March 07, 2022
OvaScience and its venture capital backer Longwood Fund have agreed to pay $15 million to resolve an investor class action saying the Massachusetts fertility company's alleged misrepresentations about the success of a new treatment eventually led to shareholder losses.
May 28, 2021
A Massachusetts federal judge said Friday securities fraud claims against a venture capital firm that was "running the show" at a fertility treatment company could go forward, rejecting arguments that the claims were late-raised by lead plaintiffs in the investor class action.
May 08, 2020
Robbins Geller Rudman & Dowd LLP must specify which attorneys will lead a suit by OvaScience investors who claim the company inflated the success of its in vitro fertilization treatment, a judge said Friday, but otherwise ruled the case fits the bill for class certification.
March 15, 2019
An OvaScience investor asked a Massachusetts federal judge on Thursday to certify a class in a suit accusing the fertility company of inflating the success of its in vitro fertilization treatment, saying its securities claims are a perfect fit for class treatment.
July 31, 2018
A Massachusetts federal judge has refused to toss a shareholder suit alleging OvaScience Inc. misrepresented the success of its in vitro fertilization treatment, saying Tuesday she was unconvinced by the company's rebuttals to investors' allegations that certain company statements were misleading.
July 16, 2018
A Massachusetts federal judge on Monday refused to let one securities class action against OvaScience Inc. take over a similar but separate class action, denying an argument that overlapping class periods could confuse investors and threaten each other's cases.
November 13, 2017
Shareholders suing OvaScience Inc. for allegedly misrepresenting the success of its fertility treatment have urged a Massachusetts federal court to keep their proposed class action alive, saying they have sufficiently detailed their claims.